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Abstract
Major histocompatibility complex class two (MHC-II) molecules are trans-membrane proteins and key
components of the cellular immune system. Upon recognition of foreign peptides expressed on the MHC-
II binding groove, helper T cells mount an immune response against invading pathogens. Therefore,
mechanistic identification and knowledge of physico-chemical features that govern interactions between
peptides and MHC-II molecules is useful for the design of effective epitope-based vaccines, as well as for
understanding of immune responses. In this paper, we present a comprehensive trans-allelic prediction
model, a generalized version of our previous biophysical model, that can predict peptide interactions for
all three human MHC-II loci (HLA-DR, HLA-DP and HLA-DQ), using both peptide sequence data and
structural information of MHC-II molecules. The advantage of this approach over other machine learning
models is that it offers a simple and plausible physical explanation for peptide-MHC-II interactions. We
train the model using a benchmark experimental dataset, and measure its predictive performance using
novel data. Despite its relative simplicity, we find that the model has comparable performance to the
state-of-the-art method. Focusing on the physical bases of peptide-MHC binding, we find support for
previous theoretical predictions about the contributions of certain binding pockets to the binding energy.
Additionally, we find that binding pockets P 4 and P 5 of HLA-DP, which were not previously considered
as primary anchors, do make strong contributions to the binding energy. Together, the results indicate
that our model can serve as a useful complement to alternative approaches to predicting peptide-MHC
interactions.
1 Introduction
Major histocompatibility complex class two (MHC-II) molecules are surface proteins that exist on the mem-
brane of antigen presenting cells-(APCs) such as macrophages, dendritic cells and B cells. They bind short
peptide fragments derived from exogenous proteins and present them to CD4+ helper T cells. Upon the
recognition of foreign peptides among those presented by MHC-II molecules, the helper-T cells will initi-
ate proper adaptive immune responses, including enabling sufficient maturation of B cells and cytotoxic
CD8+ T cells [1]. Therefore, the binding of peptide to MHC-II molecules is considered to be a fundamental
and pre-requisite step in the initiation of adaptive immunity [2, 3]. As such, mechanistic identification of
the basic determinants of peptide-MHC-II interactions presents potential for understanding the immune
system’s mechanisms and improving the process of designing peptide- and proteins-based vaccines.
MHC genes for humans, referred to as Human Leukocyte Antigen-(HLA), are among the most poly-
morphic genetic elements found within a long continuous stretch of DNA on chromosome 6 [4]. Such high
polymorphism reflects the immense contribution of MHC molecules to the adaptive immune system and
underpins their capacity to recognize a wide range of pathogens. Nonetheless, some viruses, such as hep-
atitis C, avian/swine influenza and human immunodeficiency virus (HIV), undergo extensive mutations
that allow them to escape recognition by the MHC molecules [5]. MHC genes can be divided into HLA
class I, II and III. Molecules corresponding to HLA class I are A, B and C; HLA class II molecules are DP,
DQ and DR; HLA class III genes encode for several other immune related proteins and provide support for
the former two classes [1, 4].
MHC-II molecules account for the likelihood of organ transplantation and there are well-established
associations between many disorders and particular classes of MHC-II molecules. These include the con-
tribution of HLA-DQ genes to insulin-dependent diabetes [6]; HLA-DR genes to multiple-sclerosis; and
narcolepsy [7] along with other autoimmune diseases resulting from degeneracy and misregulation in the
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process of peptide presentation [8]. Moreover, genetic and epidemiological data have implicated MHC-II
molecules in susceptibility to many infectious diseases such as HIV/AIDS, malaria [9] and cancer [10].
Experimental assays for prediction of peptide-MHC-II interactions are often faced with important ob-
stacles, including substantial resources needed for laboratory work, high time and labour demands. This
is the case in particular, for experimental work aimed at finding out which promiscuous epitopes bind to
specific MHC molecules, a necessary step in the design of peptide-based vaccines which protect against a
broad range of pathogen variants. Computational methods, which are more efficient and less costly than
biological assays, have been employed to complement these assays. Due to advances in sequencing tech-
nologies, immunological data has grown at an unprecedented pace and continues to accrue. This has been
exploited in systematic computational analyses of genomes of multiple pathogens to determine the im-
munoprotective parts that can induce a potent immune response. The results have been the design and
development of new vaccine candidates against HIV, influenza and other hyper-variable viruses [11]. Use
of computational methods has significantly reduced experimental effort and costs by up to 85% [12].
Many immunoinformatics methods for prediction of peptide-MHC interactions, for both class I and II,
have been developed based on machine learning approaches such as simple pattern motif [13], support
vector machine (SVM) [14], hidden Markov model (HMM) [15] , neural network (NN) models [16, 17],
quantitative structure–activity relationship (QSAR) analysis [18], structure-based methods, and biophysi-
cal methods [2, 19, 20, 21]. These methods can be divided into two categories, namely, intra-allele (allele-
specific) and trans-allele (pan-specific) methods. Intra-allelic methods are trained for a specific MHC allele
variant on a limited set of experimental peptide binding data and applied for prediction of peptides bind-
ing to that allele. Because of the extreme polymorphism of MHC molecules, the existence of thousands
of allele variants, especially for HLA-II genes, combined with the lack of sufficient experimental binding
data, it is impossible to build a prediction model for each allele. Thus, trans-allele and general purpose [22]
methods like MULTIRTA [2], NetMHCIIpan [17] and TEPITOPEpan [23] have been developed using richer
peptide binding data expanding over many alleles or even across species [17]. The trans-allelic models
are often designed to extrapolate either structural similarities or shared physico-chemical binding deter-
minants among HLA genes, in order to predict affinities for alleles that are not even part of the training
dataset. These models generally have better predictive performances and a wide range of potential appli-
cations compared to the intra-allelic models.
Most of the existing trans-allelic models for MHC-II are extended versions of their earlier intra-allelic
counterparts: TEPITOPEpan [23] was extended from TEPITOPE [24]; MULTIRTA [2] evolved from RTA
[19]; and the series of NetMHCIIpans (1.0, 2.0, 3.0, and 3.1) [16, 25, 17, 26] were generalized from the NN-
align [27] method. In the same vein, in this paper we present a trans-allele method, an extension of our
previous method [20], for prediction of peptide-HLA class II interactions based on biophysical ideas.
The remarkable strength of the method presented here over other existing advanced data driven ap-
proaches is it’s physical basis. We formulate the process of binding affinity between peptide and MHC-II
molecule as an inverse problem of statistical physics. From the observable macroscopic (bound and un-
bound ) states of experimental data we compute the microscopic parameters ( Hamiltonians for amino acid
residues involved in the interaction) that govern the system. In fact, many problems in computational bi-
ology can be solved in a such way [28, 29], taking advantage of the availability of vast amount of genomic
data and high resolution structural information. Solutions obtained using this approach are more plausible
and physically interpretable than those obtained using mere sequence-based methods [2, 20]. Additionally,
because sparsity is a hallmark feature of biological processes, we adjust the model’s parameters via incor-
porating an L1 regularization term into the model. The L1 constraint, commonly named Lasso, promotes
sparsity and improves the predictive performance of the model on novel data.
The rest of this paper is organized as follows: In Section 2, we describe the idea of MHC-II polymorphic
residue groups, which is employed to capture structure similarity among MHC-II alleles. In Section 3, we
define our methodology and formulate the learning function. After that we briefly describe the benchmark
dataset used to test the predictive performance of the model in Section 4 and present the results in Section
5. Finally, in Section 5.3 we summarize and discuss our results and compare our method with the state-of-
the art method.
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2 MHC-II Polymorphic Residue Groups
Crystal structures revealed that an MHC molecule is a combination of two domains, an α helix and a β
sheet, linked together to form a Y-shaped groove which is used to locate peptides, and both domains equally
contribute to the binding affinity. For HLA-I molecules, the β domain is largely conserved and variation
occurs mostly in the α domain. On the other hand, polymorphism occurs in both domains of HLA-II
molecules; except for HLA-DR alleles, where the variation takes place in the β domain. Additionally, the
peptide binding groove of the HLA-II is open at both ends, which allows binding peptides of variable
lengths, ranging from 9 to 30 amino acid residues, or even an entire protein [26, 30]. This is in contrast
to the peptide binding groove of the HLA-I alleles, which accommodate only short peptides of lengths
ranging from 8 to 11 amino acids. This flexible constraint on peptide lengths together with it’s immense
polymorphism, contribute to a lower predictive performance of computational methods for peptide-MHC-
II interactions compared to MHC-I methods [2, 22].
The notion of MHC polymorphic residue groups, introduced by Bordner et. al [2], is based on a simple
observation of an intrinsic (independent of peptide) feature of the MHC-II binding groove. Although a
peptide could bind to an MHC-II molecule in various registers, due to the open-ended nature of the MHC-
II binding groove, the strength of the binding affinity is primarily determined by 9 residues occupying
the binding groove pockets. Interestingly, most of polymorphism in MHC-II genes occurs at these binding
pockets (see the discussion in Section 5.3).
From the limited available crystallographic structural data of peptide-MHC-II complexes for a few
MHC-II molecules from the Protein Data Bank-(PDB) [31] (summarized in Table ?? in the supplemen-
tary material), sets of important positions for the polymorphic residues in the binding groove that contact
one or more peptide binding cores and are within a distance of not more than 4A˚ [2, 17, 32] in one or
more of the MHC-II complex structures can be extracted. Then, by extrapolating the similarities among
MHC molecules, their corresponding residues in different genes are determined using multiple sequence
analysis, (MSA) [33]. Exploiting the fact that HLA-DR alleles are polymorphic only in the β domain and
have the same α domain, the polymorphic residue groups for HLA-DR are extracted from its β domain
sequences. Similarly, relying on the assumption of symmetric contribution between α and β domains to
the binding affinity [2], residue groups for HLA-DP and HLA-DQ were also extracted from the β domain.
Next, the set of polymorphic residues that always co-occur at the specified positions are clustered into
the same group. The rationale of clustering polymorphic residue groups, rather than individual residues, is
to avoid over-parametrization of the model. Table ?? in the supplementary material shows such polymor-
phic residue groups for HLA-DRB, HLA-DP and HLA-DQ alleles, assembled by the procedures described
above.
3 Trans-Allele Model
In our previous intra-allele model [20] the probability of peptide P(k) to bind an MHC molecule M(T(k)) was
computed as follows:
pi(P(k),M(T(k))) =
1
1 + eδE(k)
, (1)
where δE(k) is the change in binding energy in terms of the sum of the differences of first- and second-order
Hamiltonians between the bound and unbound states. Specifically, δE(k) is given by
δE(k) =
|P(k) |∑
i=1
δH (1)(ai) +
9∑
i=1
δH (1)(bi) + δS︸                                     ︷︷                                     ︸
first-order Hamiltonians
+
per residue-residue interactions︷                          ︸︸                          ︷
|P(k) |∑
i=1
9∑
j=1
R∑
r=1
δH (2)(a(k)ir ,bj )︸                          ︷︷                          ︸
second-order Hamiltonians
, (2)
in which |P(k)| is the length of peptide k, R is the number of all possible configurations (registers) in which
the peptide binds to the particular MHC molecule, and δS is the difference in entropy between the bound
and unbound states.
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For the trans-allele model, two changes were introduced into the second term of Eq(2). First, instead
of residue-residue interaction, δH(2)(a(k)ir ,bj), with a
(k)
ir on the peptide sequence and bj on the MHC bind-
ing pocket, we rather focus on residue-polymorphic group interaction, δH(2)(a(k)ir ,gjn), where gjn is residue
group number n of position j as defined in Section 2. Next, we introduce a binary operator T(k, j,n) that
equals 1 if the MHC molecule type, M(T(k)), corresponding to peptide P(k) contains polymorphic residue
group n at the set of pre-determined positions of pocket j, and equals 0 otherwise. Hence, δE(k) is given by
δE(k) =
|P(k) |∑
i=1
δH (1)(ai) +
9∑
i=1
δH (1)(bi) + δs︸                                    ︷︷                                    ︸
first-order Hamiltonians
+
per residue-group interactions︷                                           ︸︸                                           ︷
|P(k) |∑
i=1
9∑
j=1
R∑
r=1
G(j)∑
n=1
δH (2)(a(k)ir ,gjn)T(k, j,n)︸                                           ︷︷                                           ︸
second-order Hamiltonians
, (3)
where G(j) is the number of polymorphic residue groups for binding pocket j. Column two of Table ?? in
the supplementary material shows G(j), j = 1,2, . . .9, for HLA-DR, HLA-DP, and HLA-DQ alleles.
Let ∆ denote the model’s parameters. Using Equations (1) and (3) we formulate, through the maximum
likelihood approach, the following cost function:
L(P,M|∆) = argmin
{∆}
 K∑
k=1
Gk(∆k) +λP (∆)
 , (4)
where Gk(∆) is the empirical loss function given by
Gk(∆) = yk log(pik(∆)) + (1− yk) log(1−pik(∆)), (5)
and yk ∈ {0,1} is the experimental value; y = 1 for binding peptides and y = 0 for non-binding ones. λP (∆)
is a regularization term with the form
λP (∆) = λ ||∆||1 = λ
d∑
i=1
|∆| , (6)
where λ > 0 is a hyper-parameter and d is the dimension of parameter vector ∆, which varies depending
on the type of MHC-II molecule. The L1 constraint penalty term P (∆), also known as Lasso [34], has an
important role in the model. As the model is defined on a large number of parameters ( d = 2321 , 561 and
401 for HLA-DR, HLA-DP and DQ molecules, respectively) a few parameters are expected to contribute to
the binding affinity while the rest are expected to be noisy. Lasso has the capability to filter out the noisy
parameters by inducing sparsity in the model, as it shrinks most of the parameter values to zero, and avoids
data over-fitting. The hyper-parameter λ controls the degree of sparsity of the model; the larger the value
of λ the more sparse the model. Eq(4) is a non-linear and non-smooth function; due to the L1 constraint.
But it is a convex function and we solved it, after quadratic approximation, by means of an iterative, cyclic
coordinate descent approach using a soft-thresholding operator. This learning function takes the form of
a generalized linear model and the algorithm we used to solve it is both fast and efficient. Details of this
optimization method are found in Friedman et. al [35] and are summarized in the supplementary material.
4 Binding Affinity Dataset
The model has been developed by using both quantitative peptide binding data and MHC-II molecule
sequences. We obtained a total of 51023 peptide-binding data for 24 HLA-DR, 5 HLA-DP and 6 HLA-DQ
from the IEDB database [36], which is, to the best of our knowledge, the largest benchmark dataset publicly
available in this field. This dataset was used to develop NetMHCIIpan [17], the state-of-the-art method. The
binding affinities data were given in the form of log-transformed measurements of the IC50 (half maximum
inhibition concentration) according to the formula 1 − log(IC50)/ log(50,000) [37]. We dichotomized these
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data using a moderate threshold of IC50 500 nM ( ≡ 0.426 of log-transformed data). Peptides with IC50
less than or equal 500 nM (≥ 0.426 of log-transformed value ) were considered as binders, and non-binders
otherwise.
Amino acid sequences for the MHC-II alleles used in this study were obtained from the EMBL-EBI
online-database [38], (ftp://ftp.ebi.ac.uk/pub/databases/ipd/imgt/hla/fasta ). Table 1 gives a sum-
mary of the peptide binding dataset used to develop the method.
Table 1: Overview of the MHC-II peptide binding data utilized in this study.
Allele Name HLA-Index #of peptides #of binders % of binders
HLA-DRMolecules
DRB1∗01 : 01 HLA00664 7685 4382 57.02
DRB1∗03 : 01 HLA00671 2505 649 25.91
DRB1∗03 : 02 HLA00673 148 44 29.73
DRB1∗04 : 01 HLA00685 3116 1039 33.31
DRB1∗04 : 04 HLA00689 577 336 58.23
DRB1∗04 : 05 HLA00690 1582 627 39.63
DRB1∗07 : 01 HLA00719 1745 849 48.65
DRB1∗08 : 02 HLA00724 1520 431 28.36
DRB1∗08 : 06 HLA00732 118 91 77.12
DRB1∗08 : 13 HLA00739 1370 455 33.21
DRB1∗08 : 19 HLA00745 116 54 46.55
DRB1∗09 : 01 HLA00749 1520 621 40.86
DRB1∗11 : 01 HLA00751 1794 778 43.37
DRB1∗12 : 01 HLA00789 117 81 69.23
DRB1∗12 : 02 HLA00790 117 79 67.52
DRB1∗13 : 02 HLA00798 1580 493 31.20
DRB1∗14 : 02 HLA00834 118 78 66.20
DRB1∗14 : 04 HLA00836 30 16 53.33
DRB1∗14 : 12 HLA00844 116 63 54.31
DRB1∗15 : 01 HLA00865 1769 709 40.08
DRB3∗01 : 01 HLA00887 1501 281 18.72
DRB3∗03 : 01 HLA00902 160 70 43.75
DRB4∗01 : 01 HLA00905 1521 485 31.89
DRB5∗01 : 01 HLA00915 3106 1280 41.21
HLA-DP Molecules
DPA1∗01 : 03−DPB1∗02 : 01 HLA00517 1404 538 38.32
DPA1∗01 : 03−DPB1∗04 : 01 HLA00521 1337 471 35.23
DPA1∗02 : 01−DPB1∗01 : 01 HLA00514 1399 597 42.67
Continued on next page
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Table 1 – continued from previous page
DPA1∗02 : 01−DPB1∗05 : 01 HLA00523 1410 443 31.42
DPA1∗03 : 01−DPB1∗04 : 02 HLA00522 1407 523 37.17
HLA-DQMolecules
DQA1∗01 : 01−DQB1∗05 : 01 HLA00638 1739 522 30.02
DQA1∗01 : 02−DQB1∗06 : 02 HLA00646 1629 813 49.91
DQA1∗03 : 01−DQB1∗03 : 02 HLA00627 1719 386 22.46
DQA1∗04 : 01−DQB1∗04 : 02 HLA00637 1701 559 32.86
DQA1∗05 : 01−DQB1∗02 : 01 HLA00622 1658 549 33.11
DQA1∗05 : 01−DQB1∗03 : 01 HLA00625 1689 863 51.10
Total 51023 20255 39.70
Table 1: The first column gives the names of the 34 genes used to develop the method, distributed as 24,5,6
for HLA-DR, HLA-DP and HLA-DQ genes respectively. The second column represents the index for each
allele in the EMBL-EBI database [38]. The third and fourth columns give the total number of peptide and
the number of binder peptides, receptively, per allele. The last column shows the percentage of binder
peptides. Binder peptides were identified using an IC50 binding cut-off of 500 nM, as in previous studies
[2, 16, 17, 27]. The last row presents the overall statistics for the last three columns.
5 Results
This section presents prediction results of the model obtained from the dataset of three MHC-II allotypes
as described in Section 4. We applied a five-fold cross validation analysis to the model and compared it
against its intra-allelic version (Table ?? in the supplementary material). We also examine its predictive
performance on data which were previously unseen by the model.
5.1 Performance of the trans-allele model
We tested the predictive performance of the model by using five fold cross validation. Figure 1 shows
results of the test done using alleles belonging to the three MHC-II loci considered in this study. The
performance was measured in terms of area under the curve (AUC) [39] values, which range between 0
and 1. The higher the AUC value the better the predictive performance of model. Values below 0.5 reflect
a worse performance than a random test. The model has an excellent performance for HLA-DP alleles
(average AUC value = 0.930), and a good predictive power for both HLA-DQ and HLA-DR alleles (average
AUC values = 0.830 and 0.802, respectively).
5.2 Comparing the intra-allele vs trans-allele methods
Table ?? in the supplementary material shows AUC values obtained with the intra-allele and trans-allele
versions of the model. For the intra-alleles version, the model was evaluated on peptide binding data corre-
sponding to an individual allele only. On average, the performance of the trans-allele model is comparable
to that of the intra-allele model for HLA-DP (O.930 vs 0.928), it is worse for HLA-DQ (0.830 vs 0.857) and
it is better for HLA-DR (0.780 vs 0.771) (Figure 2).
These results demonstrate two important observations. First, there is a common binding preference
among MHC-II loci, which is the basis of all trans-allelic models, and that has been successfully captured
by the definition of MHC-II polymorphic groups for HLA-DP loci, and to a lesser extent for HLA-DQ and
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AUC ROC curves for the three loci
Figure 1: (colours online) Shows Five-fold cross validation results of the model using the benchmark
dataset described in the Section 4. Three ROC curves representing the three MHC-II loci covered in this
study. The red curve for HLA-DP with AUC value = 0.930, the blue curve for HLA-DQ with AUC value
= 0.830 and the green curve for HLA-DR with AUC = 0.802.
HLA-DR. Second, the trans-allelic model is able to extrapolate similarities among the MHC-II allotypes
and achieve good predictive performance. As a result, the overall performance of the trans-allelic model is
comparable to that of intra-allele model, even though the former model is applied on a much diverse set of
MHC-II sequences.
A decreased performance of the trans-allelic model when compared with the intra-allelic method for
HLA-DQ molecules is consistent with results reported in NetMHCIIpan [17]. Here we suggest that this
is probably because of the limited structural information available for HLA-DQ alleles. In fact, because
of this limited structural information there are only 17 polymorphic residue groups for all the 9 binding
pockets defined for HLA-DQ alleles. In contrast, there are 25 and 115 polymorphic residue groups defined
for HLA-DP and HLA-DR molecules, respectively.
Another reason for the reduction of the trans-allelic model’s performance for HLA-DQ alleles is that
there is a large sequence diversity of MHC-II molecules belonging to this locus. We will examine the
empirical support for this assertion in Section5.3.
5.3 Prediction on a novel dataset
We examined the predictive power of the model on a blind dataset- i.e, a dataset which was not used in
the training phase. More precisely, to make peptide binding predictions for a particular allele, we train
the model on an entirely different allele. The allele used for training was chosen based on its similarity
to the focal allele as quantified using three different metrics: nearest neighbour, Hamming distance, and
7
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intra-allele vs trans-allele method
Figure 2: (colours online) Comparing results between the intra-alleles (gray bars) and the trans-alleles (red
bars) methods in terms of AUC values. These bars show that there is a significant increase in performance
of the trans-allele method for HLA-DR molecules and decrease for HLA-DQ molecules compared to the
intra-allele method. The difference in the HLA-DP loci is limited.
Leave-One-Out (LOO) approach.
In the nearest neighbour approach the distance between two MHC molecules is defined [16] as follows:
d(A,B) = 1− S(A,B)√
S(A,A)S(B,B)
(7)
in which S(A,B) is the score of the BLOSUM50 [40] metric between amino acid sequences of A and B. The
BLOSUM50 metric measures genetic distance between two sequences by quantifying the likelihood that
one amino acid will be substituted by another amino acid on evolutionary time scales. Hamming distance
simply counts the different occurrences of corresponding amino acid residues between two sequences. In
both nearest neighbour and Hamming metrics, we train the model on peptide data belonging to the cor-
responding nearest allele to parameterize the model, then we assess its accuracy in terms of AUC values
calculated based on peptide data belonging to the focal allele using those parameters.
However, unlike the TEPITOPE and the series of NetMHCIIpan methods which defined nearest neigh-
bour at pocket level, we derive both the nearest neighbour metric and the Hamming distance at residue
8
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level. Our choice is based on the fact that accounting for the entire MHC-II sequence provides a broader al-
lele coverage [2] and hence extend the model’s applicability. Computing sequence similarity at residue level
is an intuitive and natural approach to perform comparative analysis of sequences rather than other artifi-
cial ways that may be more computationally efficient. We found that 71% (for HLA-DR ), 60% ( HLA-DP ) ,
and 67% ( HLA-DQ ) of alleles used for training were consistent between the residue-level and pocket-level
approaches. These statistics indicate that, as mentioned before, most of MHC-II polymorphism occur at
the binding pockets.
The LOO approach involved partitioning data into two parts; the peptide binding data not belonging
to the allele under consideration are used to learn the model’s parameters and the remaining data, the
peptide binding data belonging to the focal allele, are used as test data. Figure 3 shows a comparison of
results from these three approaches (details are in Table ?? in the supplementary material). The results
show that, regardless of the metric we used, the trans-allele method has a high predictive power for HLA-
DP allele and a moderate predictive power for the other alleles.
Comparison results of the three metrics.
Figure 3: (colours online) Average performance results of the model in terms of AUC values for the three
metrics: NN approach (gray bars), Hamming metric (blue bars) and the LOO method (red bars). Except for
HLA-DQ loci, the LOO approach significantly out performs the other two metrics. Such results indicate
that this method performs better than a random test even for un-characterized MHC-II molecules.
The much higher predictive power for HLA-DP compared to the other alleles is likely due to the com-
paratively lower sequence diversity of HLA-DP alleles. To make this assertion more precise we carried out
a regression analysis by defining the AUC values from LOO approach as functions of both NN and Ham-
ming metric distances. Figure 4 gives results of our analysis. As seen in Figure 4, all HLA-DQ alleles fall
below the least squares lines for both metrics (blue points). We also found that model performance in-
creases as the distance between alleles decreases, for example, see HLA-DP allele (red points). The authors
of NetMHCIIpan also arrived at the same conclusion [17], but only for the NN metric.
9
ar
X
iv
:s
om
e
ot
he
r
te
xt
go
es
he
re
(a) NN metric (b) Hamming metric
Figure 4: (colours online) Regression analysis of AUC values from the LOO approach as function of: (a)
Nearest Neighbour and (b) Hamming distances. Negative slope lines in both graphs obtained by the least
square fit method, with p-values 0.185 and 0.0.033 for both metrics, respectively. These lines and p-values
associated with were produced using glm2 package in R [41]
5.4 Analysis of the model’s parameters
In order to determine the key factors that contribute to the binding affinities for the three MHC-II alleles
considered in this study, we calculated the Hamiltonians corresponding to each amino acid residue and the
9 binding pockets of the MHC-II binding groove. These values were then averaged over the polymorphic
residue groups defined for each pocket.
Analysis of HLA-DR parameters revealed that pocket P 1 has moderate attractive interactions with pep-
tide (negative energies indicated by blue colour in Figure 5), via hydrophobic (I, L, W, Y ) side chains and,
to lesser extent, via the aromatic (F,W) amino acids and a single hydrophilic residue (K) . Remarkably, pre-
vious studies [2, 42] arrived at a similar conclusion of a large tendency of position P 1 toward interactions
involving the hydrophobic side chains. The repulsive interactions (positive energies indicated by red colour
in Figure 5) of pocket P 1 mostly occur with the hydrophilic side chains (D, E, N, S, T) and the aliphatic
residue (A) . Generally, most of the primary anchor pockets (P 1, P 4, P 6, P 7, P 9) confer attractive interac-
tions, but the pocket P 1 makes the largest contribution. This is consistent with results obtained using the
MULTIRTA method [2]. Among the secondary anchors, we found that pocket P 2 has attractive interactions
with aromatic (F, Y) and the hydrophobic (I, M, Y) side chains. The most repulsive interactions come from
the pocket P 8, which has a strong unfavourable interactions involving the side chains of residues C, D, E,
F, G, I, L, W, and Y ( see Figure 5 (a)).
For HLA-DP, we found that pocket P 9 has significantly attractive interactions involving the hydropho-
bic residue (L). This is consistent with the previous results of [43] (see Figure 5 (b)). Also, we found that
pockets P 4 and P 5 have important attractive interactions with peptide via hydrophobic (Y) and aromatic
(F) side chains, respectively. The contributions of these two pockets were not reported in the study of
Morten et. al [43], which was specifically dedicated to HLA-DQ and HLA-DP alleles. Furthermore, we
found that the other two pockets P 1 and P 6, which were reported as primary anchors in that study, have a
moderate contribution to calculated bind energies ( see Figure 5 (b)).
The pattern of energetic contributions for HLA-DQ alleles is less ordered. There is no common pattern
except the observation of significant attractive interaction of pocket P 1 via the hydrophobic residue (W)
and the repulsive interaction of pocket P 4 via the side chains C, E, and D (see Figure 5 (c)). This finding is
in line with the observations of Morten et. al [43].
10
ar
X
iv
:s
om
e
ot
he
r
te
xt
go
es
he
re
(a) HLA-DR (b) HLA-DP (c) HLA-DQ
Figure 5: (colours online) Interaction maps for: (a) HLA-DR, (b) HLA-DP and (c) HLA-DQ molecules.
The rows give the 9 anchor positions of MHC-II binding groove and the columns give the peptide residues.
The red entries marking for repulsive interactions (positive energy), whereas the blue entries marking for
attractive interactions (negative energy). Note that most of the entries are zeros (white colour), an indication
for the degree of the sparsity of the model.
5.5 Discussion
Interactions between peptides and MHC-II molecules are central to the adaptive immune system. Precise
prediction and knowledge of the physico-chemical determinants that govern such interaction is useful in
designing effective and affordable epitope-based vaccines, and in providing insights about the immune sys-
tem’s mechanism as well as in understanding the pathogenesis of diseases. In this study we have developed
a trans-allelic model that can predict peptide interactions to the three human MHC-II loci. It can be readily
applied to MHC-II molecules of other species provided that relative structural information are available.
This method is based on biophysical ideas, an alternative to the dominant machine learning approaches.
The model presented here is, in addition to NetMHCIIpan, only the second trans-allelic method that
allows comprehensive prediction analysis of peptide binding to all three human MHC-II loci. Most trans-
allelic models for MHC-II peptides are restricted to HLA-DR and HLA-DP alleles. The TEPITOPEpan
method [23], which is popular among immunologists and is the successor of a pioneer method in this field,
is limited to HLA-DR alleles.
In this work we employed the definition of MHC polymorphic residue groups of the MULTIRTA method
[2], which is more intuitive and inclusive than the MHC pseudo sequences of NetMHCIIpan [17], in devel-
oping our trans-allelic model. Utilizing new structural data for MHC-II complexes, which were not present
when MULTIRTA was being developed, we extended that idea to cover all three human MHC-II loci.
We Compared how well our model predicts the MHC-II allele binding preferences of a novel peptide
dataset vs. how well the state-of-the-art NetMHCIIpan method performs the same task. In this comparison
we applied both our model and NetMHCIIpan to predict binding preferences for peptides known to either
bind or not bind a reference allele after training both models using peptide-binding data for a second
allele. For a given MHC-II locus, the second allele was the one that was most similar to the reference allele.
Similarity was quantified based on either a leave-one-out approach or a nearest-neighbour approach (see
Section5.3). When using the nearest-neighbour approach, we found that our model performs significantly
better than NetMHCIIpan in predicting peptide binding preferences for HLA-DQ alleles (P-value = 0.015;
Figure 6, panel A). Furthermore, at the 95% confidence level, for all other cases, we found no significant
difference between the performances of the two models (Figure 6).
These results are reassuring and indicate that our inverse-physics approach constitutes a promising
complement to the widely used pattern-based approach to peptide-MHC-II binding predictions. The out-
standing predictive accuracy of the NetMHCIIpan is not the result of its theoretical basis. Rather it derives
from the use of sophisticated ensembles of neural networks, which are very powerful. However, our method
has a distinguishing advantage over all the advanced machine learning models in that it is more physically
meaningful. It is worth noting that our prediction results of peptide-MHC-II interaction were based on
in-silico analysis of real data. Additional, in-vivo and in-vitro investigations are needed to further validate
the reported predictive performance.
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Current model vs NetMHCIIpan
Figure 6: Performance comparison between our model and NetMHCIIpan. Each model was used to predict
the probability of peptide binding to query alleles belonging to each of three HLA loci (i.e. HLA-DP,
HLA-DQ, HLA-DR) after training it using peptide-binding data for a different allele. The allele that was
most similar to the query allele was used for training. As in previous work [17], similarity between HLA
alleles was defined based on two metrics: nearest neighbor (NN) and leave-one-out (LOO). See the text
for definitions of these metrics. For each query allele, we measured each model’s predictive performance
(accounting for both sensitivity and specificity) by calculating an AUC value. The higher the AUC value
the better the predictive performance. The plot shows the average difference between the AUC values for
alleles belonging to the same locus obtained using our model vs. the corresponding values obtained using
NetMHCIIpan, when similarity is defined based on either (A) the NN or (B) the LOO metric. Error bars
denote standard deviations. Strikingly, our model performs better than NetMHCIIpan when predicting
peptide binding to HLA-DQ using the NN metric (p-value = 0.015). For all other cases, both models have
equivalent performance.
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